JPMorgan Chase & Co. Issues Positive Forecast for Establishment Labs (NASDAQ:ESTA) Stock Price

Establishment Labs (NASDAQ:ESTA) had its target price upped by analysts at JPMorgan Chase & Co. from $84.00 to $95.00 in a note issued to investors on Friday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective would suggest a potential upside of 19.72% from the stock’s previous close.

ESTA has been the subject of several other research reports. Citigroup increased their price target on Establishment Labs from $76.00 to $92.00 and gave the company a “neutral” rating in a research note on Wednesday, July 8th. Canaccord Genuity Group set a $105.00 target price on shares of Establishment Labs in a research report on Thursday. BTIG Research raised their price target on shares of Establishment Labs from $96.00 to $103.00 and gave the stock a “buy” rating in a report on Thursday. TD Cowen boosted their price target on shares of Establishment Labs from $95.00 to $117.00 and gave the stock a “buy” rating in a research report on Monday. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Establishment Labs in a research note on Wednesday, June 24th. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Establishment Labs currently has an average rating of “Moderate Buy” and a consensus target price of $100.25.

Establishment Labs Trading Up 0.4%

Shares of NASDAQ:ESTA traded up $0.30 during midday trading on Friday, hitting $79.35. 283,373 shares of the stock were exchanged, compared to its average volume of 552,277. The stock has a market capitalization of $2.34 billion, a price-to-earnings ratio of -53.29 and a beta of 1.07. The company has a debt-to-equity ratio of 16.82, a quick ratio of 1.91 and a current ratio of 2.96. The business’s 50-day moving average price is $86.29 and its 200 day moving average price is $74.23. Establishment Labs has a 12 month low of $33.35 and a 12 month high of $97.59.

Establishment Labs (NASDAQ:ESTA) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.05). Establishment Labs had a negative net margin of 19.05% and a negative return on equity of 218.77%. The business had revenue of $67.54 million during the quarter, compared to the consensus estimate of $65.79 million. During the same quarter last year, the business earned ($0.57) EPS. The firm’s quarterly revenue was up 31.7% compared to the same quarter last year. Analysts predict that Establishment Labs will post -1.07 earnings per share for the current year.

Institutional Investors Weigh In On Establishment Labs

A number of large investors have recently bought and sold shares of ESTA. KBC Group NV bought a new position in Establishment Labs in the first quarter worth approximately $28,000. Kestra Advisory Services LLC bought a new stake in shares of Establishment Labs during the fourth quarter valued at approximately $47,000. Quarry LP bought a new stake in shares of Establishment Labs during the third quarter valued at approximately $34,000. State of Wyoming acquired a new position in shares of Establishment Labs during the second quarter worth approximately $87,000. Finally, MV Capital Management Inc. acquired a new position in shares of Establishment Labs during the fourth quarter worth approximately $146,000. 72.91% of the stock is currently owned by institutional investors and hedge funds.

More Establishment Labs News

Here are the key news stories impacting Establishment Labs this week:

• Positive Sentiment: Management projected 2026 revenue of $269 million to $271 million, above the approximately $267.5 million analyst consensus. The company also said minimally invasive procedures are approaching 15% of sales, highlighting adoption of a potentially important growth area. Establishment Labs signals 2026 revenue guidance
• Positive Sentiment: Second-quarter revenue reached $67.54 million, exceeding the $65.79 million consensus estimate and increasing 31.7% from the prior-year period. The company’s loss narrowed to $0.39 per share from $0.57 a year earlier, despite missing estimates. Establishment Labs Q2 results
• Positive Sentiment: BTIG Research raised its price target from $96 to $103 and reaffirmed a Buy rating. Needham also lifted its target from $86 to $95 and assigned a Buy rating, signaling continued analyst confidence in the company’s growth outlook. Needham raises Establishment Labs price target
• Negative Sentiment: ESTA reported a quarterly loss of $0.39 per share, wider than the expected $0.34 loss. The company remains unprofitable, with a negative net margin, so investors may focus on the pace of earnings improvement and the path to profitability.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.